Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2002
03/07/2002US20020028973 Bactericides, antioxidants, and antiinflammatory agents
03/07/2002US20020028954 Useful as biodegradable surfactants and in enzymatic processes using a chitinase (N-acetylglucosaminidase)
03/07/2002US20020028953 Process for preparing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-acetic acid
03/07/2002US20020028950 Guanidinylamino heterocycle compunds useful as alpha-2 adrenoceptor agonists
03/07/2002US20020028949 Synthesis of (R)-3-(4-Bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-H-imidazo[1,2-a]imidazol-2-one
03/07/2002US20020028943 For lowering serum lipid, cholesterol and/or triglyceride levels; treating atherosclerosis
03/07/2002US20020028940 Also benzimidazolyl and imidazo(4,5-b)pyridinyl-substituted; amides; antiatherosclerotic; reduces smooth muscle cell proliferation as well as reduction in lipoproteins, cholesterol and triglycerides
03/07/2002US20020028934 Process for preparing benzoxazin-4-one polymer conjugates
03/07/2002US20020028933 Thioamide derivatives
03/07/2002US20020028927 Substituted liposaccharides useful in the treatment and prevention of endotoxemia
03/07/2002US20020028922 Chemically modified oligonucleotide for site-directed mutagenesis
03/07/2002US20020028921 Pluraflavins and derivatives thereof, process for their preparation and use thereof
03/07/2002US20020028920 Processes for preparing clarithromycin polymorphs
03/07/2002US20020028914 Chimeric toxins for targeted therapy
03/07/2002US20020028852 3 Tetra- and 1 pentahydroxylated analogs; 1-di-, 1 tri-, 3 tetra- and 1-pentamethoxylated analogs; anticarcinogenic and antiproliferative agents; inhibits cell growth; induced apoptosis
03/07/2002US20020028851 Guanylhydrazones and their use to treat inflammatory conditions
03/07/2002US20020028850 Treating chronic uremic patients undergoing periodical dialysis
03/07/2002US20020028849 Use of retinol in assisted-reproduction protocols
03/07/2002US20020028848 Administering orally 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE); anticoagulants; cardiovascular, respiratory, gastrointestinal, nervous and psyiatric disorders; autoimmune disease; antiinflammatory agents; bactericides; viricides
03/07/2002US20020028847 Administering cicaprost or iloprost to treat scleroderma; inhibiting connectie tissue growth factor (CTGF) and its related factors, including transforming growth factor (TGF-beta)
03/07/2002US20020028846 Compositions and methods for amelioration of human female sexual dysfunction
03/07/2002US20020028845 Antiinflammatory and antiarthritic agents; rheumatic diseases; side effect reduction; ulcer and allergy resistance; non-irritating; easily hydrolyzed and solubilized; bioavailability
03/07/2002US20020028844 Comprising one or more lipid-soluble forms of vitamin C, one or more water-soluble forms of vitamin C and one or more alpha-hydroxy acids; nonirritating; stability in aqueous solutions; skin penetration; patches
03/07/2002US20020028843 Mupirocin calcium amorphous as a microbiocide dissolved in a hydrophilic solvent, preferably, hexamethylene glycol; heat resistance; skin, ear and eye disorders; topical and nasal
03/07/2002US20020028841 Thienopyrrolidinones
03/07/2002US20020028840 2-indolinone derivatives as modulators of protein kinase activity
03/07/2002US20020028839 Cancer treatment with epothilones
03/07/2002US20020028838 E.g., 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7 hexahydro-pyrazolo-(4,3-c)pyridin-5-yl)-1-(R)-benzyloxymethyl- 2-oxo-ethyl)-isobutyramide; mobility impairments, e.g. identified by balance and gait, in the elderly
03/07/2002US20020028837 E.g., (2-(4-methoxyphenethyl))-N'-(2-(5-bromopyridyl))-thiourea; enzyme inhibitors of reverse transcriptase; viricides for HIV infection, including mutant, drug-sensitive, drug and multi-drug resistance strains
03/07/2002US20020028836 Potassium channel openers
03/07/2002US20020028835 Cyclic amine phenyl beta-3 adrenergic receptor agonists
03/07/2002US20020028834 Heterocyclic-cyclic amine derivatives
03/07/2002US20020028833 Aryl alkenamides derivatives as mcp-1 antagonists
03/07/2002US20020028831 Phenylpyridine derivatives useful as phosphodiesterase inhibitors
03/07/2002US20020028830 Treating proteinuria and swollen lymph node symptoms by administering an effective dose of a vitamin D analog to a patient on a diet which includes a calcium intake level of >800mg/day per 160 pound patient
03/07/2002US20020028829 Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
03/07/2002US20020028828 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
03/07/2002US20020028826 HMG-CoA reductase inhibitors and method
03/07/2002US20020028825 Preventing opioid induced inhibition of gastrointestinal motility by orally administering an enterically coated quaternary derivative of noroxymorphone, (methylnaltrexone) prior to administering an opioid such as morphine
03/07/2002US20020028823 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
03/07/2002US20020028822 Medicament for treatment of diastolic dysfunction
03/07/2002US20020028821 Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors
03/07/2002US20020028819 Piperazinedione compounds
03/07/2002US20020028818 2-nitrostyryl-1-(naphthylmethyl)sulfone for example
03/07/2002US20020028817 Platelet derived growth factors (PDGF); 1,2-dimethyl-6-(2-thiophene)imidazolo(5,4-g)quinoxaline preparations for example; use treating proliferative malignant and non-malignant diseases; stents
03/07/2002US20020028816 Containing antibiotics such as moxifloxacin; treating infections of Microbacterium species Microbacterium otitidis and Microbacterium alconae
03/07/2002US20020028815 Novel multicyclic compounds and the use thereof
03/07/2002US20020028814 Aza compounds, pharmaceutical compositions and methods of use
03/07/2002US20020028812 Phenylalanine derivatives
03/07/2002US20020028810 Substituted N-( indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
03/07/2002US20020028808 Use of potassium channel agonists for the treatment of cancer
03/07/2002US20020028807 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl) oxy)ethyl)-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one for example; inhibitor of HIV replication; treating or preventing HIV infection
03/07/2002US20020028803 Controlling cell apoptosis
03/07/2002US20020028802 Solvent extraction; plant extracts
03/07/2002US20020028800 Using a substituted indole compund and estrogen
03/07/2002US20020028799 Using protease and phospodiesterase inhibitor
03/07/2002US20020028798 Analgesics, antiinflammatory agents; mixture containing enzyme inhibitor
03/07/2002US20020028796 Adjustment mineral concentration
03/07/2002US20020028795 Prevention of ovarian cancer by administration of progestin products
03/07/2002US20020028794 Aqueous suspension; dietetics
03/07/2002US20020028793 Antilipemic agents, anticholesterol agents, anticoagulants
03/07/2002US20020028792 Combinations of bisphosphonates, estrogens and estrogenic agents
03/07/2002US20020028790 Use of agonists or antagonists of P2 purinoceptors for the prevention glutamate-evoked cytotoxicity
03/07/2002US20020028789 Topical pain relief composition and carrier
03/07/2002US20020028788 Administering estradiol in cyclodextrin adjuvant
03/07/2002US20020028787 Nervous system disorders; administering exogenous uridine compound
03/07/2002US20020028786 Methods and compositions for enhancing cellular function through protection of tissue components
03/07/2002US20020028784 Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
03/07/2002US20020028782 Cardiovascular disorders; nervous system disorders
03/07/2002US20020028781 Antibiotics
03/07/2002US20020028780 Antiparasitic formulations
03/07/2002US20020028779 Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
03/07/2002US20020028776 Polymerase inhibitor; anticancer agent
03/07/2002US20020028775 Using mixture of flavonoids, cytochrome inhibitor, sugar, phosphate in carrier
03/07/2002US20020028774 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
03/07/2002US20020028761 Neurotherapeutic use of carboxypeptidase inhibitors
03/07/2002US20020028760 Nervous system disorders; hypotensive agents; incontinence
03/07/2002US20020028514 Recombinant AAV vector-based transduction system and use of same
03/07/2002US20020028484 Expression vector for use in the treatment and prevention of viral diseases
03/07/2002US20020028473 Components of dense microspheres derived from mammalian brain tissue detectable in cerebrospinal fluid
03/07/2002US20020028449 26 Human secreted proteins
03/07/2002US20020028361 Substrate with a photocatalytic coating
03/07/2002US20020028276 Sugar-free products with improved characteristics
03/07/2002US20020028258 Extracting an active polysaccharide from a Echinacea source into an aqueous solution, precipitating a water precipitate containing the active polysaccharide from the aqueous solution; and recovering the water precipitate.
03/07/2002US20020028257 Compositions and methods for treating baldness
03/07/2002US20020028253 Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition
03/07/2002US20020028249 Preparation of biodegradable, biocompatible microparticles containing a biolgically active agent
03/07/2002US20020028248 Rapid-release microdispersible ecadotril preparation
03/07/2002US20020028247 Micro-particulate form of a tetrahydropyridin derivative
03/07/2002US20020028246 Neutral support grain coated with a mixture of morphine sulfate and of a binder, such as hydroxypropylmethylcellulose; immediate-release
03/07/2002US20020028244 Biodegradable neurotoxin implant
03/07/2002US20020028242 Paroxetine controlled release compositions
03/07/2002US20020028240 Timed-release compression-coated solid composition for oral administration
03/07/2002US20020028239 Tablet composition
03/07/2002US20020028238 Orally administration to provide a blood plasma concentration profile of celecoxib of at least about 250 mg/ml in not more than about 30 minutes
03/07/2002US20020028237 Method for reducing toxicity of a cytotoxic agent
03/07/2002US20020028235 Dermal penetration enhancer is a safe skin-tolerant ester sunscreen.
03/07/2002US20020028234 Especially medicaments containing verapamil; a lecithin/isopropyl myristate solution; butylated hydroxy toluene; pluronic F127; an antioxidant agent suspended in a carrier
03/07/2002US20020028227 Use for cosmetic and dermatological indications, reducing and soothing mucosa and skin erythema, inflammation or reaction caused by internal or external factors, wound healing, etc.
03/07/2002US20020028216 Controlled release implantable drug delivery system composed of a plurality of botulinum toxin-incorporating polymeric microspheres.